Stem Cell Cancer And Regenerative Medicine Research Inc
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2011 | 55,582 | 235,582 | −180,000 | 32.6 | 0% |
| 2012 | 144,810 | 382,047 | −237,237 | 12.6 | 0% |
| 2013 | 255,046 | 179,158 | 75,888 | 32.0 | 0% |
| 2014 | 154,720 | 202,394 | −47,674 | 25.5 | 0% |
| 2015 | 12,091 | 167,225 | −155,134 | 19.8 | 0% |
| 2016 | 100,329 | 58,571 | 41,758 | 64.9 | 0% |
| 2017 | 89,025 | 89,572 | −547 | 42.4 | 0% |
| 2018 | 129,690 | 70,834 | 58,856 | 63.6 | 0% |
| 2019 | 754,887 | 328,726 | 426,161 | 29.3 | 0% |
| 2020 | 227,703 | 340,717 | −113,014 | 24.2 | 0% |
| 2021 | 240,841 | 275,836 | −34,995 | 28.4 | 0% |
| 2022 | 18,013 | 94,674 | −76,661 | 73.1 | 0% |
| 2023 | 14,514 | 36,558 | −22,044 | 182.1 | 0% |
In its most recent public year (2023), this organization spent $22,044 more than it brought in. Its reserves stood at about 182.1 months of spending, up from 32.6 in 2011. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Stem Cell Cancer And Regenerative Medicine Research Inc's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works